Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 31

  • 1 201 clinical trials
  • 458 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia77Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Follicular lymphoma41Plasma cell myeloma refractory41Mantle cell lymphoma32Myelofibrosis31Chronic myeloid leukaemia29B-cell small lymphocytic lymphoma28Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17B-cell lymphoma refractory16B-cell type acute leukaemia16Paroxysmal nocturnal haemoglobinuria16Diffuse large B-cell lymphoma refractory14+340

Clinical trials in Blood and lymphatic system disorders

1 201 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 201 clinical trials

Thalassaemia beta+2

Recruiting

Study of SP-420 for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:(S)-4,5-Dihydro-2-[2-Hydroxy-4-(3,6-Dioxaheptyloxy)Phenyl]-4-Methyl-4-Thiazolecarboxylic Acid
  • Sponsor:Pharmacosmos A/S

Study on Mavorixafor for Patients with Chronic Neutropenia Experiencing Recurrent or Serious Infections

Recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mavorixafor
  • Sponsor:X4 Pharmaceuticals Inc.

Acute myeloid leukaemia

Recruiting

Study on Adding Sulfasalazine, Idarubicin, and Cytarabine to Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia in Patients Aged 60 and Older

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Assistance Publique Hopitaux De Paris

Chronic lymphocytic leukaemia+1

Recruiting

Long-Term Safety Study of BCMACP03, BCN-CP01, and 19CP02 for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, CLL, SLL, or Multiple Myeloma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bcmacp03
  • Sponsor:Galapagos

Plasma cell myeloma refractory

Recruiting

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Factor VIII deficiency+3

Recruiting

Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Rectal cancer+1

Recruiting

Study on the Use of Iron Oxide Nanoparticles in MRI to Detect Lymph Node Metastasis in Patients with Newly Diagnosed Rectal Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Sponsor:Varsinais-Suomen hyvinvointialue

Sickle cell disease

Recruiting

Long-term Safety and Efficacy Study of Lovotibeglogene Autotemcel Gene Therapy for Patients with Sickle Cell Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Lovotibeglogene Autotemcel
  • Sponsor:Genetix Biotherapeutics Inc.

Eosinophilic oesophagitis

Recruiting

Study on BP1.7881 for Adults with Eosinophilic Esophagitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bp1.7881A
  • Sponsor:Bioprojet Pharma

Haematological malignancy+1

Recruiting

Study on Enhanced GVH Prevention in Elderly Patients with Blood Cancer Using Rabbit Anti-Human Thymocyte Immunoglobulin During Stem Cell Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rabbit Anti-Human Thymocyte Immunoglobulin
  • Sponsor:Institut Paoli-Calmettes

Factor VIII deficiency

Recruiting

Study on Personalized Dosing of Emicizumab for Patients with Congenital Hemophilia A

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:Universitair Medisch Centrum Utrecht

Plasma cell myeloma

Recruiting

Study on Self-Administration of Elranatamab for Patients with Multiple Myeloma at Home

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Odense University Hospital

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab122 clinical trialsVenetoclax114 clinical trialsCyclophosphamide100 clinical trialsLenalidomide98 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.